Active, not recruitingPhase 1NCT05262556
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Studying Gastroenteropancreatic neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amr Mohamed MD
- Principal Investigator
- Amr Mohamed, MDUniversity Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
- Intervention
- NP-101 (TQ Formula)(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2022 – 2026
Study locations (1)
- University hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Collaborators
Novatek Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05262556 on ClinicalTrials.govOther trials for Gastroenteropancreatic neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06356467Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENsIRCCS San Raffaele
- ACTIVE NOT RECRUITINGPHASE1NCT04750954Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNANCT03012789Surgical Intervention and the NETestWren Laboratories LLC
See all trials for Gastroenteropancreatic neuroendocrine neoplasm →